Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial—Efficacy and Biomarker DiscoveryKathy S. Albain, Laura J. Esserman, Julie E. Lang et al.|Clinical Cancer Research|2023Cited by 20
Abstract PD8-07: Evaluation of Tucatinib + (Paclitaxel + Pertuzumab + Trastuzumab) followed by AC in high-risk HER2 positive (HER2+) stage II/III breast cancer: Results from the I-SPY 2 TRIALDavid A. Potter, Laura J. Esserman, Erin Roesch et al.|Cancer Research|2022Cited by 0